Mettis Global News
Mettis Global News
Mettis Global News
Mettis Global News

Trending :

BF Biosciences inks deal with Lucky Core

BF Biosciences plans to raise Rs1.38bn to 1.93bn
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

September 04, 2024 (MLN): BF Biosciences Limited (BFBL) has entered into a contract manufacturing and supply agreement with Lucky Core Industries Limited (LCI) for the products “Esopase IV 40 mg” & “Etipro IV 40 mg”, the company’s filing on PSX revealed.

BFBL is a subsidiary of Ferozsons Laboratories Limited (PSX: FEROZ).

In August, BF Biosciences successfully launched human insulin under the brand name “Ferulin”.

BF Biosciences was established exclusively for the manufacture of biologicals and it is the first and only company in Pakistan currently to have a biotech manufacturing facility.

Copyright Mettis Link News

Posted on: 2024-09-04T10:30:46+05:00